Skip to content

Remote Ischemic Conditioning for the treatment of cerebral autosomal dominant arteriopathy with sub-cortical infarct and leukoencephalopathy:A double-blind, prospective, sham-controlled, blinded endpoint,randomized clinical trial

Remote Ischemic Conditioning for the treatment of cerebral autosomal dominant arteriopathy with sub-cortical infarct and leukoencephalopathy:A double-blind, prospective, sham-controlled, blinded endpoint,randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101157
Enrollment
Unknown
Registered
2025-04-21
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy

Interventions

sham-RIC Group:sham-RIC Group
RIC Group:Remote Ischemic Conditioning or Intermittent Pressure Stimulation

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Han Chinese, between 25 and 70 years old; 2) Diagnosis of CADASIL confirmed by genetic testing; 3) moderate-to-severe white matter high signal lesions (Fazekas scale total score of 3-6); 4) Patient or caregiver reports memory or other cognitive decline lasting at least 3 months; 5) Normal or mildly impaired ability to perform activities of daily living, with a score of 10-26 on the Mini-Mental State Examination (MMSE); and a Montreal Cognitive Assessment (MOCA) score of <26, who can cooperate with treatment; 6) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Inflammatory small vessel disease; 2) Pre-onset mRS score =2; 3) History of atrial fibrillation or myocardial infarction within 6 months; 4) History of intracranial hemorrhage or severe bleeding elsewhere in the body or a severe bleeding disorder; 5) History of brain tumor, psychiatric illness, or history of acute stroke within 6 months before enrollment; 6) Severe liver or kidney disease, cancer, or critically ill patients; 7) Systolic blood pressure >185mmHg or diastolic blood pressure >110mmHg that cannot be controlled with antihypertensive drugs; 8) Any soft tissue or vascular injury and any limb disease; 9) Patients who cannot complete follow-up or are participating in other clinical trials; 10) There are contraindications to MRI, such as pacemakers, aneurysm clips, and cochlear implants, etc.

Design outcomes

Primary

MeasureTime frame
White matter hyperintensities volume;

Secondary

MeasureTime frame
Incidence of subcutaneous ecchymosis;Cognitive function;Parenchymal Brain Imaging Changes,Hemodynamic Parameters,Diffusion Tensor Imaging (DTI) Parameters;Blood Biomarkers;

Countries

China

Contacts

Public ContactBin Cai

The First Affiliated Hospital of Fujian Medical University

caibin929@163.com+86 591 87982772

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026